Novartis: nAMD drug profile reaffirmed in clinical trial
(CercleFinance.com) - Alongside the announcement of its partnership with Pfizer in the NASH liver disease, on Monday Novartis unveiled additional results confirming the positive findings on brolucizumab in patients with neovascular age-related macular degeneration (nAMD).
The phase III results from year two confirmed positive year one findings, with brolucizumab meeting its primary endpoint of non-inferiority versus aflibercept in visual acuity and exhibiting superiority in key retinal outcomes at year one, Novartis said.
Secondary endpoints at year two (96 weeks) confirmed superiority of brolucizumab in reduction of retinal fluid, an important marker of disease activity in patients with neovascular age-related macular degeneration, the Swiss drugmaker said.
"These findings at year two reaffirm the excellent year one brolucizumab data regarding retinal fluid reduction, a key goal for physicians treating patients with nAMD," reacted Dr. Pravin Dugel, an Arizona doctor and principal investigator of the trials.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The phase III results from year two confirmed positive year one findings, with brolucizumab meeting its primary endpoint of non-inferiority versus aflibercept in visual acuity and exhibiting superiority in key retinal outcomes at year one, Novartis said.
Secondary endpoints at year two (96 weeks) confirmed superiority of brolucizumab in reduction of retinal fluid, an important marker of disease activity in patients with neovascular age-related macular degeneration, the Swiss drugmaker said.
"These findings at year two reaffirm the excellent year one brolucizumab data regarding retinal fluid reduction, a key goal for physicians treating patients with nAMD," reacted Dr. Pravin Dugel, an Arizona doctor and principal investigator of the trials.
Copyright (c) 2018 CercleFinance.com. All rights reserved.